BofA lowered the firm’s price target on Fractyl Health to $22 from $26 and keeps a Buy rating on the shares after meeting up management following the company’s updates at the ADA medical meeting. Following the meetings, the firm lowered its price target as it pushed out the expected launch timeline for Revita in type-2 diabetes, or T2D, after the company said they now expect pivotal topline data for Revita in T2D in mid-2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
- Fractyl Health Updates Clinical Studies and Corporate Slides
- Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
- Fractyl Health to accelerate its REMAIN-1 clinical study
- Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions